A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin

Inclusion Criteria: Inclusion Part A: Healthy subjects * Subject is healthy without diabetes mellitus * Subject has a fasted plasma glucose (FPG) of less than 5.6 mmol/l at screening * Subject has a Body Mass Index (BMI) more than or equal to 18.5 and less than 28.0 kg/m2 * Subject's serum creatinine is within the normal range Inclusion Part A: T2DM subjects * Subject has been diagnosed with T2DM for at least 6 months * Subject's body mass index (BMI) is equal to or more than 20.0 and less than 35.0 kg/m2 at screening * Subject has a HbA1c level above 7.0% and less than 9.0% at screening * Subject has a (FPG) of less than 10.0 mmol/l * Subject is treatment naïve to glucose-lowering medication or uses metformin that will be washed out at least 3 weeks prior to the first dosing at Day 1 * Subject's serum creatinine is within the normal range Inclusion Part B: T2DM subjects * Subject has a body mass index (BMI) of more than or equal to 20.0 and less than 35.0 kg/m2 at screening. * Subject has been diagnosed with T2DM for at least 6 months * Subject has HbA1c level of equal to or more than 6.0% and less than 10% at screening * Subject has a FPG of less than 10.0 mmol/l * Subject is drug naïve or on a stable glucose lowering therapy (metformin, TZD, DPP-4 inhibitor or SUD therapy Exclusion Criteria: Exclusion Part A: Healthy subjects * Any of the liver function tests above the upper limit of normal * A QTc interval of \>430 ms (males) and \>450 ms (females), a history of unexplained syncope, cardiac arrest, unexplained significant cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS) * Abnormal pulse and/or blood pressure measurements at screening as follows: Pulse \<40 or \>90 bpm; mean systolic blood pressure \>140 mmHg; mean diastolic blood pressure \>90 mmHg * eGFR (based on Modification of Diet in Renal Disease (MDRD) method) less than 60 ml/min/1.73m2 on Day -2 Exclusion Part A \& Part B: T2DM subjects * Subject has type 1 diabetes mellitus * A QTc interval of \>450 ms (males) and \>470 ms (females), a history of unexplained syncope, cardiac arrest, unexplained significant cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS) * Subject is on an insulin therapy or has received insulin within 3 months prior to screening, with the exception of acute use of \<7 days prior to screening * Subject has a urinary microalbumin/creatinine ratio above or equal to 300 mg/g at screening * Subject has an ALT and/or AST higher than 3 times the upper limit of normal or has a total bilirubin more than 2 times the upper limit of normal at screening * Subject has a symptomatic urinary tract infection or symptomatic genito-urinary infection at screening * Subject has persistent, uncontrolled severe hypertension as indicated by a mean systolic blood pressure \> 160 mmHg or a mean diastolic blood pressure of \> 100 mmHg * Subject has significant cardiovascular disease * eGFR (based on MDRD method) less than 60 ml/min/1.73m2 on Day -2